Janssen Vaccines & Prevention B.v.

Crucell Holland B.v.

Ribovax Biotechnologies S.a.

Robert Anthony Williamson

Jehangir Wadia

Gabriel Pascual

Katarina Radosevic

Elissa Keogh

Jaap Goudsmit

Johannes P M Langedijk

Angelique Van 't Wout

Catherine Deloche

Jean-Marc Combette

Jan Willem Meijberg

Antonietta Impagliazzo

Claire Abadie

Michelle Wagner

Zhaoqing Ding

Jan Wilem Meijberg

The invention relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Antibodies and antigen-binding fragments that specifically bind to  microtubule-associated protein tau

Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the HA1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, comprising the amino acids from position y to and including the C-terminal amino acid of the HA1 domain; and (b) an influenza hemagglutinin HA2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between HA1 and HA2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza HA.

Influenza virus vaccines and uses thereof

The disclosure relates to isolated antibodies and antigen-binding fragments that bind to the G protein of RSV and which are capable of neutralizing RSV A and B subtypes, and the use thereof in the diagnosis, prophylaxis, and/or treatment of RSV infections.

Human antibodies binding to RSV G protein

The disclosure provides isolated antibodies and antigen-binding fragments that bind to the G protein of RSV and which are capable of neutralizing RSV.

Human antibodies binding to RSV G proteins

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.

Anti-human Respiratory Syncytial Virus (RSV) antibodies and methods of use

Anti-human respiratory syncytial virus (RSV) antibodies and methods of use

Antibodies against human respiratory syncytial virus (RSV) and methods of use

The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon topical administration. The invention further relates to a pharmaceutical composition comprising a fully human binding fragment of an antibody for ocular topical administration for treatment or diagnosis of an ocular disease. In particular, the antibody neutralizes HSV1 and HSV2.

Antigen binding fragments of an antibody for use in treating or diagnosing ocular diseases

Growing community of inventors

London, United Kingdom

Robert Anthony Williamson